Does Humana Cover Weight Loss Treatment in New Hampshire? A 2026 Guide

Last updated: July 19, 2026

Important. Medicare Advantage plans only: Humana offers Medicare Advantage (MA) plans in New Hampshire for adults 65 and older or those qualifying through disability. Humana does not sell commercial (under-65) health insurance in New Hampshire. If you are under 65 and looking for weight loss coverage, you may want to review guides for UnitedHealthcare NH, Anthem NH, Aetna NH, or Cigna NH instead.

If you are a Humana Medicare Advantage member in New Hampshire and wondering whether your plan may cover weight loss treatment, this guide explains what coverage may look like in 2026. Including the landmark Medicare GLP-1 Bridge program, how Humana Pharmacy Solutions (HPS) handles weight loss medications, and what New Hampshire’s electronic prescribing rules mean for controlled substances in this category.

Coverage for weight loss treatment, including GLP-1 medications like Wegovy and Zepbound, varies significantly by plan. The information below reflects general 2026 policies and may not match your specific Humana MA plan. Always verify your benefits directly with Humana before beginning treatment.

Check if You May Qualify for Weight Loss Treatment

Key facts at a glance

• Plan type: Medicare Advantage (MA) only in New Hampshire
• PBM: Humana Pharmacy Solutions (HPS)
• Governing law: CMS 42 CFR Part 422 and federal MHPAEA (not RSA 417-E:1, which applies to commercial plans only)
• Medicare GLP-1 Bridge: Starting July 1, 2026, eligible MAPD members may access Wegovy, Zepbound, or Foundayo at $50/month via CMS. Outside the standard HPS Part D formulary
• NH EPCS: RSA 318-B:21-a (Schedule II. V). Phentermine and Qsymia are Schedule IV. EPCS required in NH. GLP-1s, Contrave, and orlistat are not scheduled. EPCS does not apply.
• RSA 417-E:1: Does not apply to Medicare Advantage plans
• Medicaid disclaimer: Humana Medicare Advantage is not NH Medicaid. For NH Medicaid, contact NH DHHS at 1-800-852-3345.
• Contacts: Humana member services 1-800-448-6262 | HPS pharmacy 1-800-379-0092 | NH Insurance Department 1-800-852-3416 | CMS 1-800-633-4227

The Medicare GLP-1 Bridge: A Major 2026 Development for Humana MA Members

On July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) launched the Medicare GLP-1 Bridge program under 42 CFR Part 422. This program may allow eligible Humana Medicare Advantage Prescription Drug (MAPD) members to access FDA-approved GLP-1 weight loss medications at a cost-sharing rate of approximately $50 per month.

The three medications covered under the Medicare GLP-1 Bridge are:

• Wegovy (semaglutide 2.4 mg, weekly injection. FDA-approved for chronic weight management)
• Zepbound (tirzepatide, weekly injection. FDA-approved for chronic weight management)
• Foundayo (oral semaglutide, daily tablet. Newest GLP-1 option approved for weight management)

This coverage operates outside the standard Humana Pharmacy Solutions (HPS) Part D formulary. Historically, Medicare Part D excluded drugs used primarily for weight loss. The CMS Bridge program represents a federal policy shift that extends coverage specifically to MAPD members who meet clinical eligibility criteria, which typically include:

• BMI of 30 or higher (obesity), or BMI 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or sleep apnea
• A prescription from a licensed prescriber documenting medical necessity
• Enrollment in a qualifying Humana MAPD plan in New Hampshire

Members should contact Humana directly at 1-800-448-6262 or CMS at 1-800-633-4227 to confirm their specific plan’s participation in the GLP-1 Bridge program and to verify current eligibility criteria, as plan participation and cost-sharing details may vary.

How Humana Pharmacy Solutions (HPS) Covers Weight Loss Medications

For weight loss medications not covered under the CMS GLP-1 Bridge, Humana Medicare Advantage plans use HPS as their pharmacy benefit manager. The table below reflects how HPS typically approaches common weight loss medications in 2026, along with New Hampshire’s electronic prescribing requirements under RSA 318-B:21-a.

New Hampshire Electronic Prescribing Requirements for Weight Loss Medications

New Hampshire has one of the broadest electronic prescribing for controlled substances (EPCS) mandates in the country. Under RSA 318-B:21-a, EPCS is required for controlled substances in Schedules II through V. A significantly broader scope than federal baseline rules (which require EPCS only for Schedule II) or Hawaii’s law (HRS § 329-38.5, also limited to Schedule II).

How NH EPCS applies to weight loss medications

The practical impact on weight loss prescribing in New Hampshire depends on which medications are involved:

• GLP-1 medications (Wegovy, Zepbound, Foundayo, Ozempic): Not controlled substances. EPCS does not apply. These can be prescribed via any standard method, including telehealth platforms.
• Contrave (bupropion/naltrexone): Not a controlled substance. EPCS does not apply.
• Orlistat: Not a controlled substance. EPCS does not apply.
• Phentermine: DEA Schedule IV. EPCS is required under RSA 318-B:21-a in New Hampshire. Prescribers must use a compliant EPCS platform.
• Qsymia (phentermine/topiramate): DEA Schedule IV because it contains phentermine. EPCS is required in New Hampshire. Also subject to a REMS program requiring prescriber certification.

NH vs. HI vs. Federal EPCS comparison for phentermine/Qsymia (Schedule IV)

For the vast majority of Humana MA members pursuing GLP-1-based weight loss treatment in New Hampshire, EPCS is not a barrier. GLP-1s are not controlled substances. The EPCS requirement only becomes relevant when a prescriber recommends phentermine or Qsymia, which are rarely covered by Medicare plans and are typically prescribed for short-term use in non-Medicare populations.

RSA 417-E:1 and Why It Does Not Apply to Humana Medicare Advantage

New Hampshire’s mental health and substance use disorder parity law, RSA 417-E:1, requires commercial health insurance plans to cover mental health and substance use disorder benefits on par with medical and surgical benefits. However, this state parity law applies exclusively to commercial health insurance policies issued in New Hampshire.

Humana Medicare Advantage plans in New Hampshire are governed by federal law. Specifically CMS regulations under 42 CFR Part 422 and the federal Mental Health Parity and Addiction Equity Act (MHPAEA) as applied to Medicare Advantage plans. State statutes like RSA 417-E:1 do not govern these federal programs.

If you believe your Humana MA plan has denied coverage for weight management services in a way that may be inconsistent with federal MHPAEA requirements, you may file a complaint with CMS at 1-800-633-4227 rather than the NH Insurance Department (which handles commercial plan complaints).

Prior Authorization for Weight Loss Treatment Under Humana MA

Most GLP-1 medications and weight loss treatments under Humana Medicare Advantage plans require prior authorization (PA). The process typically involves:

1. Clinical documentation: Your prescriber documents your BMI, any weight-related comorbidities (e.g., type 2 diabetes, hypertension, sleep apnea), and previous weight management attempts.
2. Prescriber submission: Your provider submits a PA request to HPS (1-800-379-0092) or through the Humana online portal.
3. Medical necessity review: HPS reviews the request against clinical criteria. For CMS GLP-1 Bridge medications, CMS program criteria apply.
4. Determination: Humana typically issues a PA decision within 72 hours (or 24 hours for urgent requests).
5. Appeal if denied: If your PA is denied, you have the right to appeal. Contact Humana member services at 1-800-448-6262 for appeals guidance.

If a PA is denied and you believe the denial is incorrect, you may also contact the NH Insurance Department at 1-800-852-3416 for commercial plan guidance, or CMS at 1-800-633-4227 for Medicare Advantage concerns.

Weight Loss Treatments Humana MA Plans May Cover

Beyond medications, Humana Medicare Advantage plans in New Hampshire may cover a range of weight management services, depending on your specific plan:

• Obesity counseling: Many MA plans cover counseling sessions with qualified providers for obesity management, typically including dietary guidance and behavior modification.
• Telehealth weight management: Telehealth consultations for weight loss may be covered under your MA plan, including virtual visits with board-certified providers.
• Bariatric surgery: Some MA plans cover bariatric procedures (sleeve gastrectomy, Roux-en-Y gastric bypass) when medical necessity criteria are met, typically requiring a BMI above 40 or BMI above 35 with comorbidities, plus documentation of prior non-surgical weight loss attempts.
• Nutritional counseling: Medicare-covered Medical Nutrition Therapy (MNT) may be available for members with obesity-related diabetes or kidney disease.
• GLP-1 medications via CMS Bridge: Wegovy, Zepbound, or Foundayo at approximately $50/month for eligible MAPD members starting July 1, 2026.

How to Verify Your Weight Loss Coverage with Humana

1. Call Humana member services at 1-800-448-6262. Ask specifically about GLP-1 Bridge program eligibility, medication formulary coverage, and any applicable PA requirements for your plan.
2. Review your Summary of Benefits and Coverage (SBC) and Evidence of Coverage (EOC) documents, available through your Humana online account or by request.
3. Contact HPS pharmacy services at 1-800-379-0092 for formulary-specific questions about medication coverage and tier placement.
4. Consult your prescriber about whether you qualify for the CMS GLP-1 Bridge or another covered weight management treatment, and whether your prescriber is set up for NH EPCS if phentermine or Qsymia is considered.
5. Contact CMS at 1-800-633-4227 with questions specific to the Medicare GLP-1 Bridge program or to file a complaint about a Medicare Advantage coverage denial.

See If You May Qualify for Weight Loss Treatment

Get Weight Loss Support Through Klarity Health

Klarity Health connects patients with a network of 2,000+ licensed providers across the United States who offer weight management consultations via telehealth. Whether you are exploring GLP-1 medications, looking for a comprehensive weight management plan, or verifying your insurance benefits before your first appointment, Klarity’s providers can help guide your next steps.

Klarity works with patients who have Medicare Advantage coverage and can assist in navigating prior authorization processes and the CMS GLP-1 Bridge program documentation requirements.

Start with a Weight Loss Consultation

Frequently Asked Questions

Does Humana cover Wegovy or Zepbound in New Hampshire?

Starting July 1, 2026, eligible Humana MAPD (Medicare Advantage Prescription Drug) members in New Hampshire may access Wegovy, Zepbound, or Foundayo at approximately $50/month through the CMS Medicare GLP-1 Bridge program. This coverage operates outside the standard HPS Part D formulary. Eligibility typically requires a BMI of 30+ or 27+ with a qualifying comorbidity. Contact Humana at 1-800-448-6262 or CMS at 1-800-633-4227 to confirm your plan’s participation.

Does Humana sell commercial (under-65) health plans in New Hampshire?

No. Humana exited the commercial health insurance market in New Hampshire. In 2026, Humana offers Medicare Advantage plans for adults 65 and older or those qualifying through disability. If you are under 65, you may want to explore UnitedHealthcare, Anthem, Aetna, or Cigna NH plans for weight loss coverage.

Is phentermine covered by Humana Medicare Advantage?

Phentermine is rarely covered under Medicare Part D plans, including those administered by HPS. Medicare Part D has historically excluded weight loss drugs from standard coverage, and phentermine’s Schedule IV classification also means it requires EPCS in New Hampshire under RSA 318-B:21-a. For Medicare-eligible members, GLP-1 medications via the CMS Bridge are generally the more viable option.

Do I need EPCS for GLP-1 medications like Wegovy or Zepbound in New Hampshire?

No. GLP-1 medications including Wegovy, Zepbound, Foundayo, and Ozempic are not controlled substances and are not subject to NH EPCS requirements under RSA 318-B:21-a. EPCS is only required in NH for Schedule II through Schedule V controlled substances. GLP-1s can be prescribed via any standard prescribing method, including telehealth.

Does RSA 417-E:1 parity law apply to Humana Medicare Advantage plans?

No. RSA 417-E:1 is New Hampshire’s state parity law for commercial health insurance plans. Humana Medicare Advantage plans are governed by federal law under 42 CFR Part 422 and the federal MHPAEA as it applies to Medicare Advantage. Parity complaints about Humana MA coverage should be directed to CMS at 1-800-633-4227, not the NH Insurance Department.

Is Humana Medicare Advantage the same as NH Medicaid?

No. Humana Medicare Advantage is a federally regulated private insurance plan covering adults 65 and older or those qualifying through disability. It is not NH Medicaid. NH Medicaid (managed by NH DHHS) serves low-income individuals and families. For NH Medicaid information, contact NH DHHS at 1-800-852-3345.

Contact Information

• Humana Member Services: 1-800-448-6262
• Humana Pharmacy Solutions (HPS): 1-800-379-0092
• CMS (Medicare GLP-1 Bridge / MA complaints): 1-800-633-4227
• NH Insurance Department: 1-800-852-3416
• NH DHHS Medicaid: 1-800-852-3345

Medicaid disclaimer: Humana Medicare Advantage plans are not NH Medicaid. Eligibility, benefits, and cost-sharing differ significantly. For NH Medicaid (NH DHHS), call 1-800-852-3345 or visit dhhs.nh.gov.

Coverage disclaimer: Coverage for weight loss treatment, including GLP-1 medications, varies by specific Humana Medicare Advantage plan, member eligibility, medical necessity criteria, and plan year. The information in this guide reflects general 2026 policies and may not reflect your individual plan’s benefits. Always verify your benefits with Humana before beginning treatment. CMS GLP-1 Bridge participation and cost-sharing details are subject to change by CMS.